| Literature DB >> 35739948 |
Elvia Pérez-Soto1, María Olivia Medel-Flores1, Eduardo Fernández-Martínez2, Rigoberto Oros-Pantoja3, José Cruz Miranda-Covarrubias4, Virginia Sánchez-Monroy5.
Abstract
High-risk human papillomavirus (HR-HPV) infection, followed by chronic inflammation and oxidative stress, is a major risk factor of male infertility. In this study, we explored the potential impact of high-risk (HR) HPV genotypes in single infection (SI) and multiple infections (MI) that promote CYP2E1 expression, oxidative damage and pro-inflammatory cytokines, possibly contributing to sperm damage and male infertility. Semen samples from 101 infertile military men were studied. We analyzed seminal parameters, namely, HPV genotyping, cytochrome P450 2E1 (CYP2E1), oxidative stress biomarkers (total antioxidant capacity (TAC), catalase (CAT) and superoxide dismutase (SOD)), lipid peroxidation (LPO), 8-hydroxiguanosine (8-OHdG) and pro-inflammatory cytokines (IFN-γ, IL-1β, IL-4, IL-6 and IL-8). Eighty-one men (80.2%, 81/101) were positive for HPV infection, and MI-HR-HPV was higher than SI-HR-HPV (63% vs. 37%). HPV-52 was the most frequently detected type (18.5%), followed by HPV-33 (11.1%), and the most frequent combination of genotypes detected was HPV-33,52 (11.1%), followed by HPV-18,31 (6.2%). The group with infected samples presented lower normal morphology and antioxidant levels compared to non-infected samples. In concordance, the infected group showed high levels of LPO, IFN-γ, IL-1β, IL-4 and IL-6 and downregulation of CAT and SOD enzymes. Interestingly, changes in motility B, low levels of TAC, overexpression of CYP2E1, LPO and IL-8 levels were higher in MI-HR-HPV than SI-HR-HPV, suggesting that HPV infection promotes a chronic inflammatory process and a toxic and oxidative microenvironment, which increases with MI-HPV infections.Entities:
Keywords: CYP-2E1; IL-4; antioxidant enzymes; human papillomavirus; lipid peroxidation; male infertility; pro-inflammatory cytokines; sperm morphology
Year: 2022 PMID: 35739948 PMCID: PMC9219901 DOI: 10.3390/antiox11061051
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Detected HPV genotypes in semen of the HPV-positive samples in the population.
| Group | HPV Genotypes |
| Percentage (%) |
|---|---|---|---|
| Single infection | HPV52 | 15 | 18.5 |
| HPV33 | 9 | 11.1 | |
| HPV31 | 2 | 2.5 | |
| HPV6 | 2 | 2.5 | |
| HPV16 | 1 | 1.2 | |
| HPV11 | 1 | 1.2 | |
| 30 | 37.00% | ||
| Multiple infection | HPV 33, 52 | 9 | 11.1 |
| HPV 18, 31 | 5 | 6.2 | |
| HPV 16, 31, 33, 52 | 3 | 3.7 | |
| HPV 31, 52 | 2 | 2.5 | |
| HPV 16, 18 | 1 | 1.2 | |
| HPV 16, 31 | 1 | 1.2 | |
| HPV 18, 33 | 1 | 1.2 | |
| HPV 18, 52 | 1 | 1.2 | |
| HPV 18, 58 | 1 | 1.2 | |
| HPV 33, 51 | 1 | 1.2 | |
| HPV 16, 18, 33 | 1 | 1.2 | |
| HPV 16, 33, 52 | 1 | 1.2 | |
| HPV 16, 31, 52 | 1 | 1.2 | |
| HPV 33, 52, 58 | 1 | 1.2 | |
| 29 | 35.80% | ||
| Multiple infection | HPV 18, 6 | 6 | 7.4 |
| HPV 6, 52 | 3 | 3.7 | |
| HPV 11, 16 | 2 | 2.5 | |
| HPV 6, 18, 52 | 2 | 2.5 | |
| HPV 6, 11, 52 | 2 | 2.5 | |
| HPV 6, 11, 16 | 2 | 2.5 | |
| HPV 11, 16, 58 | 1 | 1.2 | |
| HPV 11, 16, 52 | 1 | 1.2 | |
| HPV 11, 33, 52 | 1 | 1.2 | |
| HPV 6, 11, 16, 18, 58 | 1 | 1.2 | |
| 27.20% |
Percentage not summed to total due to rounding; HPV: human papillomavirus; DNA: deoxyribonucleic acid.
Association between HPV positivity and semen parameters and CT positivity (n = 101).
| Test | Non-Infected HPV 1 | SI-HPV 2 | MI-HPV 3 |
|
|---|---|---|---|---|
| Volume (mL) | 2.65 ± 1.46 | 3.37 ± 1.59 | 3.11 ± 1.21 | 0.142 |
| pH | 8 [7.50, 8] | 8 [7, 8] | 8 [7, 8] | 0.135 |
| Total sperm number (×106/ejaculate) | 56 [38.0, 133.5] | 93 [38.7, 95] | 94 [51, 162.5] | 0.332 |
| Sperm concentration (×106/mL) | 28.75 [14.65, 66.00] | 28.5 [8.25, 76] | 27.5 [18, 57] | 0.819 |
| Normal morphology (%) | 5 [3, 7] | 2 [1, 3] a | 2 [1, 4] a | 0.004 |
| Abnormal sperm morphology (%) | 95 [97, 99] | 98 [97, 99] a | 98 [97, 99] a | 0.004 |
| Head defects (%) | 43.93 ± 11.20 | 42.82 ± 11.03 | 41.71 ± 12.30 | 0.737 |
| Midpiece defects (%) | 22.80 ± 13.04 | 24.82 ± 9.09 | 24.31 ± 7.90 | 0.723 |
| Tail defects (%) | 28.20 ± 16.70 | 28.21 ± 13.86 | 28.80 ± 13.42 | 0.988 |
| Total progressive motility (% A+B) | 43.64 ± 17.56 | 44.65 ± 23.05 | 45.05 ± 19.35 | 0.974 |
| Fast progressive motility (% A) | 2 [1, 41] | 2 [1, 5] | 2 [0, 3] | 0.113 |
| Low progressive motility (% B) | 6 [0, 48] | 37 [20, 52.50] | 45.50 [30, 58.75] a | 0.018 |
| Leukocytes (106) | 0.491 [0.14, 1.42] | 0.70 [0.20, 1.37] | 0.80 [0.50, 1.17] | 0.152 |
1 Infertile men without human papillomavirus infection. 2 Infertile men with single infection high-risk human papillomavirus infection. 3 Infertile men with multiple infection high-risk human papillomavirus infection. Normally distributed data are given as mean ± SD; skewed data are given as median ± [25th, 75th] percentiles. The significance tests are the ANOVA test, post hoc Tukey’s for normally distributed variables and the Kruskal–Wallis test for non-distributed variables (p < 0.05). a Infected HPV group vs. non-infected group.
Figure 1Relative gene expression to CYP2E1 in study groups. Relative expression of CYP2E1 in the non-infected group and groups with single infection (SI-HPV) or multiple infections (MI-HPV). Data are expressed as the means ± SD and were analyzed by one-way ANOVA. Significant difference was defined as p < 0.05. a Infected HPV group vs. non-infected group; b SI-HPV group vs. MI-HPV group.
Oxidative stress biomarkers in semen samples.
| Parameter | Non-Infected HPV | SI-HR-HPV | MI-HR-HPV |
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median | Percentile 25th and 75th | IQR | Median | Percentile 25th and 75th | IQR | Median | Percentile 25th and 75th | IQR | ||
| LPO (nmoles MDA/mg protein) | 3.35 | 2.51, 4.80 | 2.29 | 7.43 a | 5.55, 8.61 | 3.22 | 12.23 a,b | 6.89, 12.23 | 5.48 | 0.000 |
| 8OH-dG (ng/mL) | 8.2 | 1.85, 8.54 | 6.68 | 8.34 | 8.03, 8.80 | 0.78 | 8.20 | 7.70, 8.48 | 0.79 | 0.208 |
Abnormal distributed data are given as median, 25th and 75th percentile and interquartile range (IQR). The significance test is the Kruskal–Wallis test for non-distributed variables (p < 0.05). a Infected HPV group vs. non-infected group; b SI-HPV group vs. MI-HPV group.
Figure 2Total antioxidant capacity in study groups. The significance test is the Kruskal–Wallis test for non-distributed variables (p < 0.05). a Infected HPV group vs. non-infected group; b SI-HPV group vs. MI-HPV group.
Figure 3Relative gene expression of CAT and SOD in study groups. (A) Relative gene expression of catalase (CAT), (B) superoxide dismutase (SOD) in non-infected group, and groups with single infection (SI-HPV) or multiple infections (MI-HPV). Data are expressed as the means ± SD and were analyzed by one-way ANOVA. Significant difference is defined as p < 0.05. a Infected HPV group vs. non-infected group.
Spearman correlation analysis between OS biomarkers in seminal plasma with sperm morphology and defects in the infected population (n = 81/81, SI-HPV, MI-HPV).
| Correlation | Correlation, | |
|---|---|---|
| CYP2E1 | SI-HR-HPV, MI-HR-HPV | 0.841 **, 0.000 |
| CYP2E1 | LPO | 0.323 **, 0.005 |
| Defects in the tail | 8OH-dG | 0.246 **, 0.039 |
| CYP2E1 | TAC | −0.411 **, 0.000 |
| 8OH-dG | % Normal morphology | −0.259 *, 0.030 |
| TAC | Defects in the intermediate piece | −0.283 *, 0.020 |
| Defects in the tail | Defects in the head | −0.512 **, 0.000 |
| Defects in the tail | Defects in the intermediate piece | −0.461 **, 0.000 |
** Correlation is significant at the 0.01 level (2-tailed). * Correlation is significant at the 0.05 level (2-tailed).
Cytokines and oxidative stress biomarkers in semen samples.
| Cytokine | Non-Infected HPV | SI-HPV | MI-HPV |
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median | Percentile 25th and 75th | IQR | Median | Percentile 25th and 75th | IQR | Median | Percentile 25th and 75th | IQR | ||
| IFN-γ | 0.000 | 0.000, 0.000 | 0.000 | 398.80 a | 206.50, 909 | 704.38 | 826.50 a | 154.00, 724.00 | 571.25 | 0.000 |
| IL-1β | 0.000 | 0.000, 1.33 | 1.33 | 193.98 a | 11.33, 1303.00 | 1289.00 | 157.16 a | 0.000, 328 | 328 | 0.000 |
| IL-4 (pg/mL) | 6.25 | 0.000, 26.47 | 26.47 | 35.00 a | 22.50, 69.00 | 48.06 | 41.25 a | 17.50, 69.00 | 52.13 | 0.000 |
| IL-6 (pg/mL) | 0.000 | 0.000, 12.80 | 12.80 | 98.80 a | 0.000, 351.20 | 351.20 | 203.33 a | 36.80, 203.33 | 166.53 | 0.001 |
| IL-8 (pg/mL) | 395.45 | 0.000, 395.90 | 19.3 | 565.35 | 272.83, 917.15 | 644.3 | 550.00 a | 291.63, 1065.64 | 775.4 | 0.086 |
Abnormal distributed data are given as median, 25th and 75th percentile and interquartile range (IQR). The significance test is the Kruskal–Wallis test, p < 0.05. a Infected HPV group vs. non-infected group.